Image

Asia-Pacific Age-Related Macular Degeneration (AMD) Disease Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jun 2022
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 90
  • No of Figures: 33

Asia-Pacific Age-Related Macular Degeneration (AMD) Disease Market, By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) Industry Trends and Forecast to 2029.

Asia-Pacific Age-Related Macular Degeneration (AMD) Disease Market

Market Analysis and Insights

Asia-Pacific age-related macular degeneration (AMD) disease market is driven by the factors such as, rising geriatric population, increase in the prevalence of age-related macular degeneration (AMD) disease and increasing pipeline products which enhance its demand as well as increasing investment in research and development leads to the market growth. Currently, healthcare expenditure has increased across developed and emerging countries that is expected to create a competitive advantage for manufacturers to develop new and innovative products.

Asia-Pacific Age-Related Macular Degeneration (AMD) Disease Market

The prevalence of age-related macular degeneration, is expected to increase in developed countries due to the aging population and rising life expectancy. It is estimated that nearly 60% of patients have severe visual impairment occurring disease shortly after birth. This disease leads to blurring central vision in the patient’s eye. The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. However, the high cost associated with the treatment and procedure as well as stringent government regulations for product approval are expected to hamper the growth for age-related macular degeneration (AMD) disease market.

Asia-Pacific age-related macular degeneration (AMD) disease market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that Asia-Pacific age-related macular degeneration (AMD) disease market will grow at a CAGR of 7.2% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Year

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million

Segments Covered

By Type (Dry AMD and Wet AMD) End User(Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel(Direct Tender and Retail Sales) Industry Trends and Forecast to 2029

Countries Covered

By Country (China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2029

Market Players Covered

Novartis AG, Bayer AG, Astellas Pharma Inc., Ionis Pharmaceutics, Johnson & Johnson Services, Inc, among others

Market Definition

Age-related macular degeneration (AMD) is an eye disease that can cause damage to the macula part of the eye that controls sharp and straight-ahead vision. This leads to blurring central vision. Vision loss can be caused by abnormal blood vessel growth. Sometimes abnormal new blood vessels grow from the choroid under and into the macula. The choroid is the layer of blood vessels between the retina and the outer, firm coat of the eye (sclera). These abnormal blood vessels may leak fluid or blood, interfering with the retina's function. Macular degeneration is common in aging people. Other reasons for the rising of procedures can be defined by the increasing aging people causes and the requirement for healthcare facilities, including treatment for patient-friendly techniques for diagnosis where the medical requirements are maximum, which can further decrease the burden on healthcare facilities.

The diagnosis and treatment of age-related macular degeneration (AMD) disease consist of various techniques that allow diagnosis of the disease after the approval of the product. The treatment for the disease is recently approved, which supports the market growth. However, these treatments are expensive and not available to all patients.

Asia-Pacific Age-Related Macular Degeneration (AMD) Disease Market Dynamics

Drivers

  • Rising geriatric population

The world’s geriatric population is increasing at a rapid rate. With the increasing age comes a reciprocal increase in the number of elderly patients due to the rising prevalence of chronic disease. Age is a severe risk factor for any disease progression as age is an essential parameter that affects fundamental biological mechanisms. Therefore, aging is one of the risk factors for the Asia-Pacific incidence of early AMD.Age-related macular degeneration (AMD) can cause damage to the macula part of the eye. This leads to blur central vision. It can cause irreversible blindness and is the leading cause of visual impairment in the elderly people.

Macular degeneration is more common in aging people. The diagnosis of disease is possible at various stages and number of genetic testing and retinal imaging are some of the techniques for the detection of disease. The diagnosis of the disease is conducted mainly by optical imaging techniques and other standard process. Thus, the increasing rate of the geriatric population is expected to drive the growth of the Asia-Pacific age-related macular degeneration (AMD) disease market growth.

  • Increasing Prevalence of Age-Related Macular Degeneration (AMD) Disease

The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. These countries had reimbursement policies for age-related macular degeneration (AMD) disease market along with that increasing prevalence of genetic diseases.

Thus, it signifies that increasing prevalence of age-related macular degeneration (AMD) disease is expected to drive the Asia-Pacific age-related macular degeneration (AMD) disease market growth.

Opportunity

  •  Rising Research and Development 

Research and development is a prerequisite to modifying the treatment intended to treat different kinds of patients. The demand for age-related macular degeneration (AMD) treatment and procedures increasing worldwide involving every country Asia-Pacific. This is why the companies are continuously focusing on research and development in order to achieve success in providing effective treatment to patients and healthcare workers.

The effects can be seen only for individuals in certain ways that include effective potentiating factors such as the disease evolves, vision becomes progressively more compromised, the retinal tissue degenerates, and suffering permanent damage.

As the companies are constantly engaged in developmental activities more innovative products are launched in the market. This thus signifies that increasing research and development is expected as an opportunity for the Asia-Pacific age-related macular degeneration (AMD) disease growth. The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the Asia-Pacific age-related macular degeneration (AMD) disease market.

Restraint/Challenge

  • High cost of aesthetic surgical procedures

The cost of the product plays a major factor in the market. In the age-related macular degeneration (AMD) disease, it is generally observed that they are highly sophisticated, need to be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. Utilizations of critical care and intensive care unit services are increasing worldwide, along with their expensive cost is a major concern in the current healthcare system.

Patients with degeneration disorder are commonly required to have long treatment with frequent monetarization and other usage leading to consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment.  But this increases the possibilities and susceptibilities for new complications in the diagnosis which demands additional healthcare resources and treatment. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with age-related macular degeneration (AMD) disease treatment and diagnosis is expected to restrain the Asia-Pacific age-related macular degeneration (AMD) disease market growth.

Recent Developments

  • In January 2022, Genentech, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of wet AMD and DME.This will help the company to commercialize the product in the market in the forecast period.
  • In April 2022, Graybug Vision Inc. announced that the company has presented a poster presentation preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting for GB-401 in primary open-angle glaucoma (POAG). This will increase the chances for safety and evaluation of drug in the market.

Asia-Pacific Age-related Macular Degeneration (AMD) Disease Market Segmentation

Asia-Pacific age-related macular degeneration (AMD) disease market is categorized into is categorized into three notable segments which are based on type, end user and distribution channel. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

  • Dry AMD
  • Wet AMD

On the basis of type, the Asia-Pacific age-related macular degeneration (AMD) disease market is segmented into dry AMD and wet AMD.

End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Others

On the basis of end user, the Asia-Pacific age-related macular degeneration (AMD) disease market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare and others.

Distribution Channel

  • Retail Sales
  • Direct Tender

Age-Related Macular Degeneration (AMD) Disease Market

On the basis of distribution channel, the Asia-Pacific age-related macular degeneration (AMD) disease market is segmented into retail sales and direct tender.

Age-related macular degeneration (AMD) disease market Regional Analysis/Insights

The age-related macular degeneration (AMD) disease market is analysed and market size insights and trends are provided by type, end user and distribution channel as referenced above.

The countries covered in the age-related macular degeneration (AMD) disease report are China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.

China is expected to dominate due to increasing technological advancement in the developing areas.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Age-Related Macular Degeneration (AMD) Disease Market Share Analysis

Asia-Pacific age-related macular degeneration (AMD) disease market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on age-related macular degeneration (AMD) disease market.

 Some of the players in the market are Novartis AG, Bayer AG, Astellas Pharma Inc., Ionis Pharmaceutics, Johnson & Johnson Services, Inc, among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 VARIOUS EXAMPLES OF OPHTHALMIC DEVICES ARE SUMMARIZED IN THE BELOW-GIVEN TABLE ACCORDING TO THEIR CLASSIFICATION

TABLE 2 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 18 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 20 ASIA-PACIFIC MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 22 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 23 ASIA-PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 24 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 25 CHINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 26 CHINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 27 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 29 CHINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 30 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 31 JAPAN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 32 JAPAN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 35 JAPAN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 36 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 INDIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 INDIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 41 INDIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 SOUTH KOREA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 SOUTH KOREA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 46 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 47 SOUTH KOREA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 48 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 AUSTRALIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 AUSTRALIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 AUSTRALIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 54 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 SINGAPORE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 SINGAPORE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 58 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 59 SINGAPORE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 60 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 THAILAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 THAILAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 65 THAILAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 66 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 INDONESIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 INDONESIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 69 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 70 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 71 INDONESIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 72 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 PHILIPPINES WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 PHILIPPINES MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 76 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 77 PHILIPPINES RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 78 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 MALAYSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 MALAYSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 82 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 83 MALAYSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 84 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 85 VIETNAM WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 VIETNAM MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 88 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 89 VIETNAM RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 90 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions